Alison Mcvie-wylie PhD

Alison McVie-Wylie is the Vice President, Disease Area Executive, Duchenne Muscular Dystrophy at Vertex. Prior to Vertex, Alison led Preclinical Development at Exonics Therapeutics and served as the Head of Rare Disease Gene Therapy and Biologics Pharmacology at Sanofi-Genzyme. Alison was the lead Scientist responsible for the nonclinical development of Myozyme from early concept to marketing approval. Alison obtained her Ph.D. in Molecular Genetics from the University of Glasgow, Scotland.